Recent Finacing
Recent Raise
Hopewell Therapeutics develops a ttLNP lipid nanoparticle platform from an ionizable lipid library and Tufts-licensed IP to create systemically administered LNPs targeting extrahepatic tissues, initially for pulmonary diseases.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
